Drug & intervention
eribulin mesylate
RxCUI 1045452
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Loading RxNorm relationships…
Clinical trials
40 shownEribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast CancerNCT05530057 · 2020-02-18
RECRUITINGTesting the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast CancerNCT06590558 · 2025-08-04
WITHDRAWNA Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)NCT05374512 · 2022-05-16
ACTIVE_NOT_RECRUITINGGrapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast CancerNCT05041101 · 2021-12-21
TERMINATEDMaintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer PatientsNCT04502680 · 2021-06-01
UNKNOWNEribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerNCT04624711 · 2021-03-01
UNKNOWNTesting the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast CancerNCT04345913 · 2021-03-01
ACTIVE_NOT_RECRUITINGSafety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerNCT05206656 · 2020-10-09
COMPLETEDEribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast CancerNCT05546255 · 2020-06-01
UNKNOWNBreast Cancer Treatment Based on Organ-like CultureNCT03925233 · 2019-01-02
UNKNOWNSecond Line ERIbulin Followed by CApecitabine or the Reverse Sequence in HER2-negative Metastatic Breast Cancer PatientsNCT05833919 · 2018-07-30
UNKNOWNM7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast CancerNCT03579472 · 2018-05-30
TERMINATEDA Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast CancerNCT03583944 · 2018-03-28
COMPLETEDA Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer ParticipantsNCT03437083 · 2018-01-25
COMPLETEDA Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerNCT03051659 · 2017-03-22
COMPLETEDA Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and TaxanesNCT03412955 · 2017-03-08
UNKNOWNStudy of Eribulin Mesylate in Combination With PEGylated Recombinant Human Hyaluronidase (PEGPH20) Versus Eribulin Mesylate Alone in Subjects With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative, High-Hyaluronan (HA) Metastatic Breast Cancer (MBC)NCT02753595 · 2016-07-13
TERMINATEDRebastinib Plus Antitubulin Therapy With Paclitaxel or Eribulin in Metastatic Breast CancerNCT02824575 · 2016-07-01
TERMINATEDTreatment of Brain Metastases From Breast Cancer With Eribulin MesylateNCT02581839 · 2015-11-17
COMPLETEDStudy to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)NCT02513472 · 2015-08-28
COMPLETEDStudy to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerNCT02481050 · 2015-06-16
COMPLETEDEribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast CancerNCT02120469 · 2014-10-01
COMPLETEDPAINTER: Polymorphism And INcidence of Toxicity in ERibulin TreatmentNCT02864030 · 2014-05-01
COMPLETEDHalaven Patient Registry (Metastatic Breast Cancer, MBC)NCT03245112 · 2014-03-03
UNKNOWNEribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast CancerNCT02037529 · 2014-01-17
SUSPENDEDEribulin Mesylate in Treating Patients With Previously Treated Metastatic Breast CancerNCT01908101 · 2014-01-08
COMPLETEDEribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast CancerNCT01961544 · 2013-06-01
COMPLETEDEribulin in Combination With Capecitabine for Adjuvant Treatment in Estrogen Receptor-Positive Early Stage Breast CancerNCT01439282 · 2011-08-01
COMPLETEDCarboplatin and Eribulin Mesylate in Triple Negative Breast Cancer PatientsNCT01372579 · 2011-08-01
UNKNOWNPost-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)NCT01463891 · 2011-07-19
COMPLETEDDose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast CancerNCT01328249 · 2011-03-03
COMPLETEDAn Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer RefractoryNCT01240421 · 2011-03-01
APPROVED_FOR_MARKETINGA Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast CancerNCT01268150 · 2011-02-01
COMPLETEDEribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast CancerNCT01269346 · 2010-12-01
COMPLETEDCompassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed TherapiesNCT01142661 · 2010-08-01
COMPLETEDEribulin Mesylate Administered in Combination With Pemetrexed Versus Pemetrexed Alone as Second Line Therapy in Patients With Stage IIIB or IV Nonsquamous Non Small Cell Lung CancerNCT01126736 · 2010-06-10
COMPLETEDA Confirmation Study of Eribulin in Combination With CapecitabineNCT01323530 · 2010-01-26
COMPLETEDA Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast CancerNCT00879086 · 2009-03-31
COMPLETEDStudy of E7389 for Advanced or Metastatic Breast CancerNCT00965523 · 2008-01-01
COMPLETEDE7389 in Treating Patients With Recurrent or Progressive Stage IIIB or Stage IV Non-Small Cell Lung CancerNCT00400829 · 2006-11-01
COMPLETEDConditions being studied
Breast Cancer11Metastatic Breast Cancer9Anatomic Stage IV Breast Cancer AJCC v83Metastatic Triple-Negative Breast Carcinoma3Stage IV Breast Cancer3Advanced Breast Cancer2Anatomic Stage III Breast Cancer AJCC v82Breast Adenocarcinoma2Breast Neoplasms2HER2-negative Breast Cancer2HER2/Neu Negative2Invasive Breast Carcinoma2Recurrent Breast Carcinoma2Triple Negative Breast Cancer2Unresectable Triple-Negative Breast Carcinoma2Adenocarcinoma of the Prostate1Adverse Drug Event1Brain Metastases1Breast Cancer Organoids1Breast Inflammatory Carcinoma1
Research locations
New YorkNew York, United States8HoustonTexas, United States7DallasTexas, United States6San AntonioTexas, United States6AtlantaGeorgia, United States4BostonMassachusetts, United States4ChicagoIllinois, United States4DenverColorado, United States4DuarteCalifornia, United States4LebanonNew Hampshire, United States4MadisonWisconsin, United States4MiamiFlorida, United States4
Leading sponsors
Eisai Inc.13National Cancer Institute (NCI)4Eisai Co., Ltd.2Eisai Korea Inc.2M.D. Anderson Cancer Center2The First Affiliated Hospital with Nanjing Medical University2Academic and Community Cancer Research United1AstraZeneca1Case Comprehensive Cancer Center1Chang Gung Memorial Hospital1Chinese Academy of Medical Sciences1City of Hope Medical Center1Consorzio Oncotech1Dana-Farber Cancer Institute1Eisai Limited1
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.